NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes

Georgios Ponirakis, Maria N. Odriozola, Samantha Odriozola, Ioannis N. Petropoulos, Shazli Azmi, Maryam Ferdousi, Hassan Fadavi, Uazman Alam, Andrew Marshall, Maria Jeziorska, Anthony Miro, Ahmad Kheyami, Mitra Tavakoli, Ahmed Al-Ahmar, Maria B. Odriozola, Ariel Odriozola, Rayaz Malik

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. Methods: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. Results: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabetic patients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82%-84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%-76%). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%-78%) and low for neuropathic pain (AUC: 63%-65%). Conclusions: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.

Original languageEnglish
Pages (from-to)800-805
Number of pages6
JournalDiabetes Technology and Therapeutics
Volume18
Issue number12
DOIs
Publication statusPublished - 1 Dec 2016

Fingerprint

Neuralgia
Diabetic Neuropathies
Peripheral Nervous System Diseases
Area Under Curve
Neural Conduction
Vibration
Equipment and Supplies
Nerve Fibers
Economics
Costs and Cost Analysis

Keywords

  • Diabetic peripheral neuropathy
  • Diagnostic device
  • NerveCheck
  • Quantitative sensory testing

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes. / Ponirakis, Georgios; Odriozola, Maria N.; Odriozola, Samantha; Petropoulos, Ioannis N.; Azmi, Shazli; Ferdousi, Maryam; Fadavi, Hassan; Alam, Uazman; Marshall, Andrew; Jeziorska, Maria; Miro, Anthony; Kheyami, Ahmad; Tavakoli, Mitra; Al-Ahmar, Ahmed; Odriozola, Maria B.; Odriozola, Ariel; Malik, Rayaz.

In: Diabetes Technology and Therapeutics, Vol. 18, No. 12, 01.12.2016, p. 800-805.

Research output: Contribution to journalArticle

Ponirakis, G, Odriozola, MN, Odriozola, S, Petropoulos, IN, Azmi, S, Ferdousi, M, Fadavi, H, Alam, U, Marshall, A, Jeziorska, M, Miro, A, Kheyami, A, Tavakoli, M, Al-Ahmar, A, Odriozola, MB, Odriozola, A & Malik, R 2016, 'NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes', Diabetes Technology and Therapeutics, vol. 18, no. 12, pp. 800-805. https://doi.org/10.1089/dia.2016.0279
Ponirakis, Georgios ; Odriozola, Maria N. ; Odriozola, Samantha ; Petropoulos, Ioannis N. ; Azmi, Shazli ; Ferdousi, Maryam ; Fadavi, Hassan ; Alam, Uazman ; Marshall, Andrew ; Jeziorska, Maria ; Miro, Anthony ; Kheyami, Ahmad ; Tavakoli, Mitra ; Al-Ahmar, Ahmed ; Odriozola, Maria B. ; Odriozola, Ariel ; Malik, Rayaz. / NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes. In: Diabetes Technology and Therapeutics. 2016 ; Vol. 18, No. 12. pp. 800-805.
@article{23b276e0fd0e437cadf542d690d3d741,
title = "NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes",
abstract = "Background: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. Methods: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. Results: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabetic patients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82{\%}-84{\%}) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60{\%}-76{\%}). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69{\%}-78{\%}) and low for neuropathic pain (AUC: 63{\%}-65{\%}). Conclusions: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.",
keywords = "Diabetic peripheral neuropathy, Diagnostic device, NerveCheck, Quantitative sensory testing",
author = "Georgios Ponirakis and Odriozola, {Maria N.} and Samantha Odriozola and Petropoulos, {Ioannis N.} and Shazli Azmi and Maryam Ferdousi and Hassan Fadavi and Uazman Alam and Andrew Marshall and Maria Jeziorska and Anthony Miro and Ahmad Kheyami and Mitra Tavakoli and Ahmed Al-Ahmar and Odriozola, {Maria B.} and Ariel Odriozola and Rayaz Malik",
year = "2016",
month = "12",
day = "1",
doi = "10.1089/dia.2016.0279",
language = "English",
volume = "18",
pages = "800--805",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes

AU - Ponirakis, Georgios

AU - Odriozola, Maria N.

AU - Odriozola, Samantha

AU - Petropoulos, Ioannis N.

AU - Azmi, Shazli

AU - Ferdousi, Maryam

AU - Fadavi, Hassan

AU - Alam, Uazman

AU - Marshall, Andrew

AU - Jeziorska, Maria

AU - Miro, Anthony

AU - Kheyami, Ahmad

AU - Tavakoli, Mitra

AU - Al-Ahmar, Ahmed

AU - Odriozola, Maria B.

AU - Odriozola, Ariel

AU - Malik, Rayaz

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. Methods: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. Results: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabetic patients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82%-84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%-76%). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%-78%) and low for neuropathic pain (AUC: 63%-65%). Conclusions: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.

AB - Background: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. Methods: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain. Results: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception threshold (WPT) were significantly lower (P ≤ 0.0001) in diabetic patients with DPN compared to patients without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]: 82%-84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%-76%). The diagnostic accuracy of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%-78%) and low for neuropathic pain (AUC: 63%-65%). Conclusions: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits, comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.

KW - Diabetic peripheral neuropathy

KW - Diagnostic device

KW - NerveCheck

KW - Quantitative sensory testing

UR - http://www.scopus.com/inward/record.url?scp=85006971644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006971644&partnerID=8YFLogxK

U2 - 10.1089/dia.2016.0279

DO - 10.1089/dia.2016.0279

M3 - Article

VL - 18

SP - 800

EP - 805

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 12

ER -